T1	Participants 385 444	influence of MTX on infliximab exposure in patients with AS
T2	Participants 454 516	Patients with AS patients who had predominantly axial symptoms
T3	Participants 1133 1166	Twenty-six patients were included
T4	Participants 1546 1563	patients with AS.
